(Total Views: 470)
Posted On: 07/01/2021 12:09:23 AM
Post# of 145879
Quote:
Anyways, I think there is something else, that BP is saying you want those inflammatory non-classical, S1 presenting monocytes adhering to endothelial walls to stay put so as to keep the inflammation from spreading to vessels in the brain and heart.
Those monocytes elsewhere will send out cytokines to call macrophages and monocytes to that site. No chemotaxi because CCL5 and CCL4 are blocked.
Quote:
I wonder if BP is correct about wanting to use both a statin to lower fractalkine and CCR5i to block monocyte motility (no matter that he says low motility is a cause of PASC). or maybe will CCR5i alone lower fractalkine and inhibity damaging non-classical monocyte motility?
I've never tried to hunt down the level of effect CCR5 has on fractalkine but with the effect on TNF-a and IFNy it should be significant and our longhaulers trial seems to support that.
![](/m/images/thumb-up.png)
![](/m/images/thumb-down.png)